BUZZ - Johnson & Johnson shares rise after the company announces positive results from arthritis drug clinical trials
路透社2026/11/20 17:36November 20 - ** Johnson & Johnson (JNJ.N) shares rose 1.4% in afternoon trading to $270.94 after the company announced positive results from a clinical trial of a drug for treating arthritis
** JNJ is on track to end a four-session losing streak
** The company (link) announced its anti-inflammatory drug “TREMFYA” delivered clinically meaningful improvements, including reductions in symptoms reported by patients across several domains such as spinal pain, stiffness, fatigue, joint symptoms, and tender areas
** According to data compiled by London Stock Exchange Group (LSEG), 26 analysts cover Johnson & Johnson (JNJ), with an average rating of “buy” and a median target price of $281.78
** Johnson & Johnson (JNJ) has risen 31% so far this year, while the S&P 500 Health Care Index .SPXHC has gained 15.5% in the same period
(To assist non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for readers’ convenience. Reuters is not liable for any damage or loss arising from the use of automated translation functions.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-PayPal appoints Clare Bramley as Chief Financial Officer, shares drop
Aster Reports Coordinated Trading Behind 15% Spike and Dual Liquidations

